Résultats de la recherche - Francesco Almerigogna
- Résultat(s) 1 - 2 résultats de 2
-
1
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity par Marco Caminati, Alessandra Vultaggio, Andrea Matucci, Gianenrico Senna, Francesco Almerigogna, Diego Bagnasco, Fulvia Chieco‐Bianchi, Filippo Cosini, Domenico Girelli, Gabriella Guarnieri, Francesco Menzella, Claudio Micheletto, Oliviero Olivieri, Gianni Passalacqua, Laura Pini, Oliviero Rossi, Andrea Vianello, Emanuele Vivarelli, Ernesto Crisafulli
Publié 2020Artigo -
2
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Cli... par Giusy Tiseo, Chiara Barbieri, Valentina Galfo, Sara Occhineri, Tommaso Matucci, Francesco Almerigogna, Jona Kalo, Pietro Sponga, Mario Cesaretti, G. Marchetti, Arianna Forniti, Claudio Caroselli, Simone Ferranti, Manuela Pogliaghi, Maria Cristina Polidori, Silvia Fabiani, Stefano Verdenelli, Enrico Tagliaferri, Niccolò Riccardi, L Suardi, Claudia Carmignani, Serena Batini, Luca Puccetti, Riccardo Iapoce, Francesco Menichetti, Marco Falcone
Publié 2022Artigo
Outils de recherche:
Sujets similaires
Internal medicine
Medicine
Adverse effect
Antiretroviral therapy
Asthma
Clinical endpoint
Clinical trial
Cohort
Coronavirus disease 2019 (COVID-19)
Disease
Environmental health
Exacerbation
Human immunodeficiency virus (HIV)
Immunology
Infectious disease (medical specialty)
Observational study
Outpatient clinic
Pediatrics
Population
Proportional hazards model
Ritonavir
Viral load